MeCure Industries Redeems N3bn Senior Secured Bond

MeCure Industries Plc, has successfully redeemed its N3 billion senior secured bond issued under its N20 billion debt issuance programme.

This showcase the company’s strong financial discipline and commitment to meeting its obligations to investors. The bond, originally issued on May 14, 2021, marked the Company’s debut transaction in the Nigerian capital market.

The Company stated this in a statement signed by its Company secretary/legal adviser, Olawale Ibitoye. According to the statement, the full repayment underscores MeCure’s strong financial discipline, robust cash flow management, and commitment to meeting its obligations to investors.

Speaking on the milestone, the chief financial officer of MeCure Industries, Ifedamola Oluwasegun said, “the successful redemption of our Series 1 bond is a significant achievement for MeCure. It reflects not only our financial resilience but also the confidence that the capital markets placed in us during our debut issuance. We are proud to have honored this obligation in full and on schedule.”

He added, “the Company delivered a solid performance in 2025, driven by operational efficiency, expanded market reach, and continued investment in manufacturing capabilities. As we look ahead, we are optimistic about 2026, with a strong pipeline of opportunities that will support sustainable growth and long-term value creation.”

Since its issuance, the Series 1 bond has played a key role in supporting MeCure’s strategic initiatives, including capacity expansion, product development, and strengthening its distribution network across Nigeria and export markets.

This milestone reinforces MeCure’s position as a credible and disciplined issuer in the Nigerian capital market, setting a strong foundation for future engagements with investors as the Company continues to pursue its growth ambitions.

Established in 2005, MeCure Industries Plc is a leading force in Nigeria’s pharmaceutical sector, pioneering the production and distribution of high-quality, affordable healthcare solutions. With an emphasis on accessibility, innovation, and quality, the Company aims to address Nigeria’s critical healthcare needs through the local production of a broad spectrum of pharmaceutical products.